Ahmed ElNawawi serves as Executive Vice President and Chief Commercial Officer at Geron Corporation, a late-stage biopharmaceutical company focused on advancing innovative therapies for hematologic malignancies. With over 25 years of experience in the biopharmaceutical industry, ElNawawi joined Geron in 2023 to lead the company's commercial strategy ahead of the anticipated U.S. launch of imetelstat, branded as Rytelo, the first telomerase inhibitor approved by the FDA in June 2024 for adult patients with low- to intermediate-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. His appointment underscores Geron's transition from a clinical-stage company to a commercial entity, leveraging his proven track record in launching and scaling oncology and hematology products in rare disease markets. Prior to Geron, ElNawawi held senior leadership roles at Incyte Corporation, where he served as Senior Vice President and Head of U.S. Hematology, driving commercial success for key franchises including Jakafi (ruxolitinib) and Opzelura (ruxolitinib cream), contributing to significant revenue growth and market expansion in myelofibrosis and other blood disorders. Earlier in his career, he was Vice President of Commercial for Hematology/Oncology at Jazz Pharmaceuticals, overseeing the U.S. launch of Vyxeos for acute myeloid leukemia, and held progressive commercial leadership positions at Pfizer and Sanofi, specializing in rare diseases and oncology. His achievements include multiple successful product launches, team-building in high-growth environments, and strategic partnerships that have accelerated patient access to transformative therapies. At Geron, ElNawawi is responsible for building and leading the global commercial organization, including sales, marketing, market access, and medical affairs functions. He plays a pivotal role in the successful rollout of Rytelo, ensuring rapid adoption among hematologists and optimizing reimbursement strategies to address unmet needs in MDS. Under his leadership, Geron has established a robust commercial infrastructure, positioning the company for sustained growth and potential expansion into additional indications, such as myelofibrosis, reflecting his expertise in navigating complex regulatory and payer landscapes.